Long-term Outcomes of Faricimab in Previously Treated Neovascular Age-related Macular Degeneration

The aim of this study was to evaluate long-term outcomes of intravitreal faricimab injections (IFIs) in previously treated neovascular age-related macular degeneration (nAMD).

This retrospective cohort included 204 eyes from 178 patients with nAMD previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Clinical and imaging data were collected at baseline, after three injections, 1 year, 2 years, and final follow-up.

Patients were followed for 2.5 ± 0.3 years. Central subfield thickness decreased from 267.6 ± 61.0 µm to 225.8 ± 42.1 µm (P < .001), and treatment intervals extended from 6.5 ± 2.4 to 11.5 ± 8.0 weeks (P < .001). Intraretinal fluid declined from 44.5% to 29.5% (P = .048) and subretinal fluid from 67.5% to 36.8% (P < .001), while vision and pigment epithelial detachment height remained stable. Switching from faricimab to another agent provided no added benefit.

Faricimab demonstrated sustained anatomical improvement and treatment durability over 2.5 years, with a subset of patients showing lasting benefit.